Osteoporosis and sarcopenia in patients with rheumatoid arthritis: the ways to prevent musculoskeletal loss

Cover Page

Cite item

Full Text

Abstract

Rheumatoid arthritis (RA) is one of the most common and serious chronic immunoinflammatory diseases, leading to early disability of patients and the high levels of premature mortality. Patients with RA along with osteoporosis and osteopenia have shown significant reductions in muscle mass of sarcopenia and/or cachexia.Musculoskeletal loss in RA causes a high risk of falls and fractures, which significantly worsens the prognosis. In the article the basic pathogenetic mechanisms of the development of osteoporosis and sarcopenia in RA risk factors, as well as the main approaches to treatment and prevention of bone and muscle loss in RA patients are covered.

About the authors

A. A Muradyants

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: elitarsoft@list.ru
канд. мед. наук, доц. каф. факультетской терапии им. акад. А.И.Нестерова лечебного фак-та ГБОУ ВПО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

N. A Shostak

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: shostakkaf@yandex.ru
д-р мед. наук, проф., зав. каф. факультетской терапии им. акад. А.И.Нестерова лечебного фак-та ГБОУ ВПО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

A. A Kondrashov

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: kaartem@gmail.com
ассистент каф. факультетской терапии им. акад. А.И.Нестерова лечебного фак-та ГБОУ ВПО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

V. T Timofeev

N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation

Email: vtt3@yandex.ru
д-р мед. наук, глав. науч. сотр. научно- исследовательской лаб. «Ревматические заболевания» каф. факультетской терапии им. акад. А.И.Нестерова лечебного фак-та ГБОУ ВПО РНИМУ им. Н.И.Пирогова 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1

References

  1. Ревматология. Клинические рекомендации. Под ред. Е.Л.Насонова. М.:ГЭОТАР-Медиа, 2010; с. 90-230.
  2. Мikuls T.R, Fay B.T, Michaud K et al. Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology (Oxford) 2011; 50: 101-9.
  3. Насонов Е.Л., Скрипникова И.А., Насонова В.А. Проблема остеопороза в ревматологии. М.: Стин, 1997.
  4. Gough A.K, Lilley J, Eyre S et al. Generalized bone loss in patient with early rheumatoid arthritis. Lancet 1994; 344 (8914): 23-7.
  5. Goldring S.R. The effects of inflammatory arthritis on bone remodeling. Arthritis Res 2005; 7 (Suppl. 1): S12.
  6. Bezerra M.C, Carvalho J.F, Prokopowitsch A.S, Pereira R.M. RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz J Med Biol Res 2005; 38 (2): 161-70
  7. Forsblad d'Elia H, Larsen A, Waltbrand E et al. Radiographic joint destruction in postmenopausal rheumatoid arthritis is strongly associated with generalised osteoporosis. Ann Rheum Dis 2003; 62 (7): 617-23.
  8. Solomon D.H, Finkelstein J.S, Shadick N et al. The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis: the osteoporosis in rheumatoid arthritis (OPiRA) cohort study. Arthr Rheum 2009; 60: 1624-31.
  9. Fardellone P, Séjourné A, Paccou J, Goëb V. Bone Remodelling Markers in Rheumatoid Arthritis. Med Inflam 2014, Article ID 484280. http://dx.doi.org/10.1155/2014/484280
  10. Таскина Е.А., Алексеева Л.И., Дыдыкина И.С. и др. Факторы риска развития остеопороза у больных ревматоидным артритом. Науч. - практ. ревматология. 2014; 52 (4): 393-7.
  11. Гукасян Д.А., Балабанова Р.М., Смирнов А.В., Насонов Е.Л. Изучение взаимосвязи между минеральной плотностью костной ткани и клинико - лабораторными показателями активности ревматоидного артрита. Науч. - практ. ревматология. 2005; 1: 18-21.
  12. Sinigaglia L, Nervetti A, Mela Q et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. J Rheumatol 2000; 27: 2582-9.
  13. Güler-Yüksel M, Allaart C.F, Goekoop-Ruiterman Y.P et al. Changes in hand and generalised bone mineral density in patients with recent - onset rheumatoid arthritis. Ann Rheum Dis 2009; 68 (3): 330-6.
  14. Deodhar A.A, Woolf A.D. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 1996; 35 (4): 309-22.
  15. Мурадянц А.А., Шостак Н.А. Вторичный остеопороз: особенности течения и терапии при ревматоидном артрите. Вестн. РГМУ. 2005; 8 (47): 70-4.
  16. Беневоленская Л.И. Проблема остеопороза в современной медицине. Науч. - практ. ревматология. 2005; 1: 4-7.
  17. Haugeberg G, Strand A, Kvien T.K, Kirwan J.R. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo - controlled trial. Arch Intern Med 2005; 165 (11): 1293-7.
  18. Habib G.S, Haj S. Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids. Clin Rheumatol 2005; 24 (2): 129-33.
  19. Kanis J.A, Burlet N, Cooper C et al. European guidance for the diagnosis and management of оsteoporosis in postmenopausal women. Osteoporos Int 2008; 19: 399-428.
  20. Van Staa T.P, Geusens P, Bijlsma J.W et al. Clinical assessment of the long - term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54: 3104-12.
  21. Evans W.J, Morley J.E, Argiles J et al. Cachexia: a new defenition. Clin Nutr 2008; 27 (6): 793-9.
  22. Cruz-Jentoft A.J, Baeyens J.P, Bauer J.M et al. Sarcopenia: European consensus on definition and diagnosis Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39 (4): 412-23.
  23. Baumgartner R.N, Koehler K.M, Romero L.J et al. Epidemiology of sarcopenia in elderly people in New Mexico. Am J Epidemiol 1998; 147: 744-63.
  24. Roubenoff R. Sarcopenia: effects on body composition and function. J Gerontol A Biol Sci Med Sci 2003; 58 (11): 1012-7.
  25. Giles J.T, Allison M, Blumenthal R.S et al. Abdominal adiposity in rheumatoid arthritis: Association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 2010; 62 (11): 3173-82.
  26. Marcora S.M, Chester K.R, Mittal G et al. Randomized phase 2 trial of anti - tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. Am J Clin Nutr 2006; 84: 1463-72.
  27. Crepaldi G, Maggi S. Sarcopenia and osteoporosis: A hazardous duet. J Endocrinol Invest 2005; 28 (10): 66-8.
  28. Binkley N, Buehring B. Beyond FRAX: it's time to consider "sarco - osteopenia". J Clin Densitom 2009; 12: 413-6.
  29. Drey M, Sieber C.C, Bertsch T et al. Osteosarcopenia is more than sarcopenia and osteopenia alone. Aging Clin Exp Res 2015 Nov 12. [Epub ahead of print]
  30. Walsh M.C, Hunter G.R, Livingstone M.B. Sarcopenia in premenopausal and postmenopausal women with osteopenia, osteoporosis and normal bone mineral density. Osteoporos Int 2006; 17: 61-7.
  31. Di Monaco M, Vallero F, Di Monaco R, Tappero R. Prevalence of sarcopenia and its association with osteoporosis in 313 older women following a hip fracture. Arch Gerontol Geriatr 2011; 52: 71-4.
  32. Kostoglou-Athanassiou I, Athanassiou P, Lyraki A et al. Vitamin D and rheumatoid arthritis. Ther Adv Endocrinol Metab 2012; 3 (6): 181-7.
  33. Burton L.A, Sumukadas D. Optimal management of sarcopenia. Clin Interv Aging 2010; 5: 217-28.
  34. Jankosky C, Deussing E, Gibson R, Haverkos H. Viruses and vitamin D in the etiology of type 1 diabetes mellitus and multiple sclerosis. Virus Res 2012; 163: 424-30.
  35. Smolen J.S, Breedveld F.C, Burmester G.R et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016; 75 (1): 3-15.
  36. Vis M, Güler-Yüksel M, Lems W.F. Can bone loss in rheumatoid arthritis be prevented? Osteoporosis Int 2013; 24 (10): 2541-53.
  37. Minaur N.J, Kounali D, Vedi S et al. Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatol (Oxford) 2002; 41 (7): 741-9.
  38. Di Munno O, Mazzantini M, Sinigaglia L et al. Effect of low dose methotrexate on bone density in women with rheumatoid arthritis: results from a multicenter cross - sectional study. J Rheumatol 2004; 31 (7): 1305-9.
  39. O’Dell J.R, Mikuls T.R, Taylor T.H et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med 2013; 369 (4): 307-18.
  40. Kobayashi Y, Ueyama S, Arai Y et al. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone - resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage. J Bone Miner Metab 2004; 22 (4): 318-28.
  41. Sakthiswary R, Das S. The effects of TNF a antagonist therapy on bone metabolism in rheumatoid arthritis: a systematic review. Curr Drug Targ 2013; 14 (13): 1552-7.
  42. Chopin F, Garnero P, le Henanff A et al. Long - term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67 (3): 353-7.
  43. Kim S.Y, Schneeweiss S, Liu J et al. Effects of disease - modifying antirheumatic drugs on nonvertebral fracture risk in rheumatoid arthritis: A population - based cohort study. J Bone Min Res 2012; 27 (4): 789-96.
  44. Kume K, Amano K, Yamada S et al. The effect of tocilizumab on bone mineral density in patients with methotrexate - resistant active rheumatoid arthritis. Rheumatol 2014; 53 (5): 900-3.
  45. Garnero P, Thompson E, Woodworth T et al. Rapid and sustained improvement in bone and cartilage turnover markers with the anti - interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double - blind, placebo - controlled trial of tocilizumab in inadequate responders to methotrexate alone. Arthritis Rheum 2010; 62 (1): 33-43.
  46. Wheater G, Hogan V.E, Teng Y.K et al. Suppression of bone turnover by B-cell depletion in patients with rheumatoid arthritis. Osteoporosis Int 2011; 22 (12): 3067-72.
  47. Klein R.G, Arnaud S.B, Gallagher J.C et al. Intestinal absorption in exogenous hypercortisolism: role of 25-hydroxyvitamin D and corticosteroid dose. J Clin Invest 1977; 60: 253-9.
  48. Reid I.R, Bolland M.J, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta - analysis. Lancet 2014; 383 (9912): 146-55.
  49. Avenell A, Mak J.C, O’Connell D. Vitamin D and vitamin D analogues for preventing fractures in post m enopausal women and older men. Cochrane Database Syst Rev 2014; 4.
  50. Gallagher J.C, Sai A, Templin T et al. Dose response to vitamin D supplementation in postmenopausal women: a randomized trial. Annals of Internal Medicine 2012; 156 (6): 425-37.
  51. Van Hemelrijck M, Michaelsson K, Linseisen J et al. Calcium intake and serum concentration in relation to risk of cardiovascular death in NHANES III. PLoS One 2013; 8 (4): e61037.
  52. Choy E, Ganeshalingam K, Semb A.G et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatol 2014; 53 (12): 2143-54.
  53. Nieves J.W. Skeletal effects of nutrients and nutraceuticals, beyond calcium and vitamin D. Osteoporos Int 2013; 24 (3): 771-86.
  54. Okyay E, Ertugrul C, Acar B et al. Comparative evaluation of serum levels of main minerals and postmenopausal osteoporosis. Maturitas 2013; 76 (4): 320-5.
  55. Zheng J, Mao X, Ling J et al. Low serum levels of zinc, copper, and iron as risk factors for osteoporosis: a meta - analysis. Biol Trace Elem Res 2014; 160 (1): 15-23.
  56. Nielsen F.H, Hunt C.D, Mullen L.M et al. Effect of dietary boron on mineral, estrogen, and testosterone metabolism in postmenopausal women. FASEB 1987; J1: 394-7.
  57. Демидов В.И., Жидоморов Н.Ю., Громова О.А. и др. Роль кальция, витамина D3 и остеотропных минералов в профилактике и комплексном лечении перелома берцовой кости: результаты рандомизированного плацебо - контролируемого эксперимента. Лечащий врач. 2014; 12.
  58. Evstigneyeva L, Kozhemyakina E, Lesnyak O et al. Effect of Exercise for Patient with Osteoporotic Vertebral Fractures. Ann Rheum Dis 2013; 72 (Suppl. 3): A137-A1372.
  59. De Jong Z, Munneke M, Lems W.F et al. Slowing of bone loss in patients with rheumatoid arthritis by long - term high - intensity exercise: results of a randomized, controlled trial. Arthritis Rheum 2004; 50 (4): 1066-76.
  60. Lemmey A.B, Williams S.L, Marcora . et al. Are the benefits of a high - intensity progressive resistance training program sustained in rheumatoid arthritis patients? A 3-year followup study. Arthritis Care Res 2012; 64 (1): 71-5.
  61. Lemmey A.B, Marcora ., Chester K et al. Effects of high - intensity resistance training in patients with rheumatoid arthritis: A randomized controlled trial. Arthritis Care Res 2009; 61 (12): 1726-34.
  62. Rall L.C, Meydani ., Kehayias . et al. The effect of progressive resistance training in rheumatoid arthritis. Increased strength without changes in energy balance or body composition. Arthritis Rheum 1996; 39 (3): 415-26.
  63. Waters D.L, Baumgartner R.N, Garry P.J et al. Advantages of dietary, exercise - related, and therapeutic interventions to prevent and treat sarcopenia in adult patients: an update. Clin Interv Aging 2010; 5: 259-70.
  64. Romas E. Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates. Best Pract Res Clin Rheum 2005; 19 (6): 1065-79.
  65. Suzuki Y. Secondary osteoporosis. Bisphosphonates as a possible strategy for the prevention of bone destruction in rheumatoid arthritis. Clin Calcium 2007; 17 (12): 1909-13.
  66. Sambrook P.N, Cameron I.D, Chen J.S et al. Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five - year study. Osteopor Int 2011; 22 (9): 2551-6.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies